pdatanews

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

Yes at 87% and No at 13% on Kalshi as of 22:26 UTC on 20 Nov 2026.

Kalshi·Finance
United States
marketsingle market
Yes 87¢
No 13¢

If the FDA's decision on Lorundrostat by Mineralys Therapeutics on or before December 22, 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

a full approval or an accelerated approval · prices over time
−24h
now
volume · 24h windows
no volume history

This is a single yes or no market on Kalshi in the finance category and it asks: What will the FDA's decision be on Lorundrostat by Mineralys Therapeutics on or before December 22, 2026? Over the last day Yes rose six points and the market shows a spread of eight points between the best bid and ask. Trading on Kalshi is due to end on 23 December 2026 and Kalshi-reported volume is 1.1 contracts over the last day and 71 contracts since this finance market opened. This market is tracked by pdata.world next to twenty-four related events on Kalshi, Polymarket, Manifold and Limitless including the Polymarket event titled FDA approves Retatrutide this year. Price history for this Kalshi finance market is available from pdata.world as JSON and through its MCP server.

similar markets

suggested by pdata